



Human Cytomegalovirus Vaccine Development: Progress and Prospects

Guest Editor:

Dr. Donald J. Alcendor

Center for AIDS Health Disparities
Research, Department of
Microbiology, Immunology and
Physiology, Meharry Medical
College, Nashville, TN 37208, USA

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Human cytomegalovirus (HCMV) is classified as a beta herpesvirus that undergoes latency, is ubiquitous in the general population, and can cause life-threatening disease in individuals who have a dysfunctional immune system. Most babies around the world with congenital HCMV disease are born to women who were seropositive prior to conception. Clinically, there are a number of antiviral medications used to treat acute HCMV disease. However, during pregnancy and under conditions of immune suppression, antivirals are not the standard of care. Therefore, the development of novel vaccines to prevent HCMV infections is vital, particularly in specific patient populations such as pregnant people, especially adolescent girls less than 20 years of age who are at risk of primary infection, the elderly, and those with compromised immune systems. Safe and effective vaccines for HCMV has been elusive; however, recent innovations in mRNA technologies and proteomics have advanced the field.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com